Advertisement

Novel associations between inflammation-related proteins and adiposity: A targeted proteomics approach across four population-based studies

Published:November 12, 2021DOI:https://doi.org/10.1016/j.trsl.2021.11.004
      Chronic low-grade inflammation has been proposed as a linking mechanism between obesity and the development of inflammation-related conditions such as insulin resistance and cardiovascular disease. Despite major advances in the last 2 decades, the complex interplay between immune regulators and obesity remains poorly understood. Therefore, we aimed to identify novel inflammation-related proteins associated with adiposity. We investigated the association between BMI and waist circumference and 72 circulating inflammation-related proteins, measured using the Proximity Extension Assay (Olink Proteomics), in 3,308 participants of 4 independent European population-based studies (KORA-Fit, BVSII, ESTHER, and Bialystok PLUS). In addition, we used body fat mass measurements obtained by Dual-energy X-ray absorptiometry (DXA) in the Bialystok PLUS study to further validate our results and to explore the relationship between inflammation-related proteins and body fat distribution. We found 14 proteins associated with at least one measure of adiposity across all 4 studies, including 4 proteins for which the association is novel: DNER, SLAMF1, RANKL, and CSF-1. We confirmed previously reported associations with CCL19, CCL28, FGF-21, HGF, IL-10RB, IL-18, IL-18R1, IL-6, SCF, and VEGF-A. The majority of the identified inflammation-related proteins were associated with visceral fat as well as with the accumulation of adipose tissue in the abdomen and the trunk. In conclusion, our study provides new insights into the immune dysregulation observed in obesity that might help uncover pathophysiological mechanisms of disease development.
      To read this article in full you will need to make a payment

      References

        • Reilly SM
        • Saltiel AR
        Adapting to obesity with adipose tissue inflammation.
        Nat Rev Endocrinol. 2017; 13: 633-643https://doi.org/10.1038/nrendo.2017.90
        • Lee YS
        • Wollam J
        • Olefsky JM
        An integrated view of immunometabolism.
        Cell. 2018; 172: 22-40https://doi.org/10.1016/j.cell.2017.12.025
      1. Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. front cardiovasc med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022.

        • Meier CA
        • Bobbioni E
        • Gabay C
        • Assimacopoulos-Jeannet F
        • Golay A
        • Dayer J-M
        IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?.
        J Clin Endocrinol Metab. 2002; 87: 1184-1188https://doi.org/10.1210/jcem.87.3.8351
        • Kim C-S
        • Park H-S
        • Kawada T
        • et al.
        Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.
        Int J Obes. 2006; 30: 1347-1355https://doi.org/10.1038/sj.ijo.0803259
        • Bruun JM
        • Verdich C
        • Toubro S
        • Astrup A
        • Richelsen B
        Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men.
        Eur J Endocrinol. 2003; 148: 535-542https://doi.org/10.1530/eje.0.1480535
        • Zhang X
        • Yeung DCY
        • Karpisek M
        • et al.
        Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.
        Diabetes. 2008; 57: 1246-1253https://doi.org/10.2337/db07-1476
        • Bastard J-P
        • Jardel C
        • Bruckert E
        • et al.
        Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss*.
        J Clin Endocrinol Metab. 2000; 85: 3338-3342https://doi.org/10.1210/jcem.85.9.6839
        • Lee M-J
        • Wu Y
        • Fried SK
        Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications.
        Mol Aspects Med. 2013; 34: 1-11https://doi.org/10.1016/j.mam.2012.10.001
      2. Holle R, Happich M, Löwel H, Wichmann HE. KORA–a research platform for population based health research. Gesundheitswes (Bundesverband der Arzte des Offentl Gesundheitsdienstes. 2005;67 Suppl 1:S19-25. https://doi.org/10.1055/s-2005-858235

      3. Himmerich S, Gedrich K, Karg G. Bayerische Verzehrsstudie (BVS) II Abschlussbericht. München Tech Univ München. Published online 2004.

        • Löw M
        • Stegmaier C
        • Ziegler H
        • Rothenbacher D
        • Brenner H
        Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER-Studie) TT - Epidemiological investigations of the chances of preventing, recognizing early and opt.
        Dtsch Med Wochenschr. 2004; 129: 2643-2647https://doi.org/10.1055/s-2004-836089
        • Jung K
        • Friede T
        • Beissbarth T
        Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes.
        BMC Bioinformatics. 2011; 12: 288https://doi.org/10.1186/1471-2105-12-288
        • Sales AC
        Review: mediation Package in R.
        J Educ Behav Stat. 2017; 42: 69-84
        • Rehman J
        • Considine R V
        • Bovenkerk JE
        • et al.
        Obesity is associated with increased levels of circulating hepatocyte growth factor.
        J Am Coll Cardiol. 2003; 41: 1408-1413https://doi.org/10.1016/S0735-1097(03)00231-6
        • Mohan T
        • Deng L
        • Wang B-Z.
        CCL28 chemokine: An anchoring point bridging innate and adaptive immunity.
        Int Immunopharmacol. 2017; 51: 165-170https://doi.org/10.1016/j.intimp.2017.08.012
      4. Van Alsten SC, Rabkin CS, Sawada N, et al. Metabolic syndrome, physical activity and inflammation: a cross-sectional analysis of 110 circulating biomarkers in japanese adults. Cancer Epidemiol Biomarkers & Prev. Published online January 1, 2020:cebp.1513.2019. https://doi.org/10.1158/1055-9965.EPI-19-1513.

        • Kitahara CM
        • Trabert B
        • Katki HA
        • et al.
        Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance.
        Cancer Epidemiol Biomarkers Prev. 2014; 23: 2840-2849https://doi.org/10.1158/1055-9965.EPI-14-0699-T
        • Huber J
        • Kiefer FW
        • Zeyda M
        • et al.
        CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity.
        J Clin Endocrinol Metab. 2008; 93: 3215-3221https://doi.org/10.1210/jc.2007-2630
        • Dahlman I
        • Kaaman M
        • Olsson T
        • et al.
        A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects.
        J Clin Endocrinol Metab. 2005; 90: 5834-5840https://doi.org/10.1210/jc.2005-0369
        • Gögebakan Ö
        • Osterhoff MA
        • Schüler R
        • et al.
        GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial.
        Diabetologia. 2015; 58: 1759-1768https://doi.org/10.1007/s00125-015-3618-4
        • Madani R
        • Karastergiou K
        • Ogston NC
        • et al.
        RANTES release by human adipose tissue in vivo and evidence for depot-specific differences.
        Am J Physiol Metab. 2009; 296: E1262-E1268https://doi.org/10.1152/ajpendo.90511.2008
        • Catalán V
        • Gómez-Ambrosi J
        • Ramirez B
        • et al.
        Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass.
        Obes Surg. 2007; 17: 1464-1474https://doi.org/10.1007/s11695-008-9424-z
        • Breslin WL
        • Johnston CA
        • Strohacker K
        • et al.
        Obese Mexican American children have elevated MCP-1, TNF-α, monocyte concentration, and dyslipidemia.
        Pediatrics. 2012; 129: e1180-e1186https://doi.org/10.1542/peds.2011-2477
        • Kitahara CM
        • Trabert B
        • Katki HA
        • et al.
        Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance.
        Cancer Epidemiol Biomarkers Prev. 2014; 23: 2840-2849https://doi.org/10.1158/1055-9965.EPI-14-0699-T
        • Browning LM
        • Krebs JD
        • Magee EC
        • Frühbeck G
        • Jebb SA.
        Circulating markers of inflammation and their link to indices of adiposity.
        Obes Facts. 2008; 1: 259-265https://doi.org/10.1159/000169832
        • Herder C
        • Schneitler S
        • Rathmann W
        • et al.
        Low-grade inflammation, obesity, and insulin resistance in adolescents.
        J Clin Endocrinol Metab. 2007; 92: 4569-4574https://doi.org/10.1210/jc.2007-0955
        • Herder C
        • Müller-Scholze S
        • Rating P
        • et al.
        Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).
        Eur J Endocrinol. 2006; 154: 311-317https://doi.org/10.1530/eje.1.02090
        • Sekikawa A
        • Kadowaki T
        • Curb JD
        • et al.
        Circulating levels of 8 cytokines and marine n-3 fatty acids and indices of obesity in Japanese, white, and Japanese American middle-aged men.
        J Interferon Cytokine Res. 2010; 30: 541-548https://doi.org/10.1089/jir.2009.0114
        • Donnelly RP
        • Sheikh F
        • Kotenko S V
        • Dickensheets H.
        The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain.
        J Leukoc Biol. 2004; 76: 314-321https://doi.org/10.1189/jlb.0204117
        • Braune J
        • Weyer U
        • Hobusch C
        • et al.
        IL-6 Regulates M2 polarization and local proliferation of adipose tissue macrophages in obesity.
        J Immunol. 2017; 198: 2927-2934https://doi.org/10.4049/jimmunol.1600476
        • Elias I
        • Franckhauser S
        • Bosch F.
        New insights into adipose tissue VEGF-A actions in the control of obesity and insulin resistance.
        Adipocyte. 2013; 2: 109-112https://doi.org/10.4161/adip.22880
        • Trøseid M
        • Seljeflot I
        • Arnesen H.
        The role of interleukin-18 in the metabolic syndrome.
        Cardiovasc Diabetol. 2010; 9: 11https://doi.org/10.1186/1475-2840-9-11
        • Doupis J
        • Rahangdale S
        • Gnardellis C
        • Pena SE
        • Malhotra A
        • Veves A.
        Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors.
        Obesity (Silver Spring). 2011; 19: 729-735https://doi.org/10.1038/oby.2010.193
        • Zafar MI
        • Mills K
        • Ye X
        • et al.
        Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis.
        Diabetol Metab Syndr. 2018; 10: 62https://doi.org/10.1186/s13098-018-0363-0
        • Ashman LK.
        The biology of stem cell factor and its receptor C-kit.
        Int J Biochem Cell Biol. 1999; 31: 1037-1051https://doi.org/10.1016/S1357-2725(99)00076-X
        • Björkbacka H
        • Yao Mattisson I
        • Wigren M
        • et al.
        Plasma stem cell factor levels are associated with risk of cardiovascular disease and death.
        J Intern Med. 2017; 282: 508-521https://doi.org/10.1111/joim.12675
        • Huang Z
        • Ruan H-B
        • Xian L
        • et al.
        The stem cell factor/Kit signalling pathway regulates mitochondrial function and energy expenditure.
        Nat Commun. 2014; 5: 4282https://doi.org/10.1038/ncomms5282
        • Yao G-Q
        • Sun BH
        • Weir EC
        • Insogna KL.
        A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis.
        Calcif Tissue Int. 2002; 70: 339-346https://doi.org/10.1007/s00223-001-1079-x
        • Yasuda H
        • Shima N
        • Nakagawa N
        • et al.
        Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
        Proc Natl Acad Sci U S A. 1998; 95: 3597-3602https://doi.org/10.1073/pnas.95.7.3597
        • Kanamaru F
        • Iwai H
        • Ikeda T
        • Nakajima A
        • Ishikawa I
        • Azuma M.
        Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells.
        Immunol Lett. 2004; 94: 239-246https://doi.org/10.1016/j.imlet.2004.05.010
        • Cao JJ.
        Effects of obesity on bone metabolism.
        J Orthop Surg Res. 2011; 6: 30https://doi.org/10.1186/1749-799X-6-30
        • Karsenty G.
        Convergence between bone and energy homeostases: Leptin regulation of bone mass.
        Cell Metab. 2006; 4: 341-348https://doi.org/10.1016/j.cmet.2006.10.008
        • Jin J
        • Wang Y
        • Jiang H
        • Kourkoumelis N
        • Renaudineau Y
        • Deng Z.
        The impact of obesity through fat depots and adipokines on bone homeostasis.
        AME Med Journal. 2018; Vol 3 (Ame Med J. Published online 2018)
        • Xu F
        • Du Y
        • Hang S
        • Chen A
        • Guo F
        • Xu T.
        Adipocytes regulate the bone marrow microenvironment in a mouse model of obesity.
        Mol Med Rep. 2013; 8: 823-828https://doi.org/10.3892/mmr.2013.1572
        • Halade G V
        • El Jamali A
        • Williams PJ
        • Fajardo RJ
        • Fernandes G.
        Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice.
        Exp Gerontol. 2011; 46 (https://doi.org/): 43-52https://doi.org/10.1016/j.exger.2010.09.014
        • Kibble M
        • Khan SA
        • Ammad-ud-din M
        • et al.
        An integrative machine learning approach to discovering multi-level molecular mechanisms of obesity using data from monozygotic twin pairs.
        R Soc Open Sci. 2020; 7200872https://doi.org/10.1098/rsos.200872
        • Pons V
        • Laflamme N
        • Préfontaine P
        • Rivest S.
        Role of macrophage colony-stimulating factor receptor on the proliferation and survival of microglia following systemic nerve and cuprizone-induced injuries.
        Front Immunol. 2020; 11: 47https://doi.org/10.3389/fimmu.2020.00047
        • Levine JA
        • Jensen MD
        • Eberhardt NL
        • O'Brien T
        Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth.
        J Clin Invest. 1998; 101: 1557-1564https://doi.org/10.1172/JCI2293
        • Pixley FJ
        • Stanley ER.
        CSF-1 regulation of the wandering macrophage: complexity in action.
        Trends Cell Biol. 2004; 14: 628-638https://doi.org/10.1016/j.tcb.2004.09.016
        • Bartocci A
        • Mastrogiannis DS
        • Migliorati G
        • Stockert RJ
        • Wolkoff AW
        • Stanley ER.
        Macrophages specifically regulate the concentration of their own growth factor in the circulation.
        Proc Natl Acad Sci. 1987; 84 (LP - 6183): 6179https://doi.org/10.1073/pnas.84.17.6179
        • Merry TL
        • Brooks AES
        • Masson SW
        • et al.
        The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice.
        Int J Obes. 2020; 44: 245-253https://doi.org/10.1038/s41366-019-0355-7
        • Hume DA
        • MacDonald KPA.
        Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling.
        Blood. 2012; 119: 1810-1820https://doi.org/10.1182/blood-2011-09-379214
        • Hamilton JA.
        Colony-stimulating factors in inflammation and autoimmunity.
        Nat Rev Immunol. 2008; 8: 533-544https://doi.org/10.1038/nri2356
        • Chitu V
        • Stanley ER.
        Colony-stimulating factor-1 in immunity and inflammation.
        Curr Opin Immunol. 2006; 18: 39-48https://doi.org/10.1016/j.coi.2005.11.006
        • Eiraku M
        • Hirata Y
        • Takeshima H
        • Hirano T
        • Kengaku M.
        Delta/notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons.
        J Biol Chem. 2002; 277: 25400-25407https://doi.org/10.1074/jbc.M110793200
      5. Schlesinger S, Herder C, Kannenberg JM, et al. General and abdominal obesity and incident distal sensorimotor polyneuropathy: insights into inflammatory biomarkers as potential mediators in the KORA F4/FF4 cohort. diabetes care. 2019;42:240-247. doi:10.2337/dc18-1842

        • Dragovich MA
        • Mor A.
        The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases.
        Autoimmun Rev. 2018; 17: 674-682https://doi.org/10.1016/j.autrev.2018.01.018
        • Magnusson L
        • Espes D
        • Casas R
        • Carlsson P-O.
        Increased plasma levels of the co-stimulatory proteins CDCP1 and SLAMF1 in patients with autoimmune endocrine diseases.
        Front Immunol. 2020; 11: 1916https://doi.org/10.3389/fimmu.2020.01916
        • Ziegler D
        • Strom A
        • Bönhof GJ
        • et al.
        Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy.
        BMJ Open Diabetes Res & Care. 2019; 7e000752https://doi.org/10.1136/bmjdrc-2019-000752
        • Afonina IS
        • Müller C
        • Martin SJ
        • Beyaert R.
        Proteolytic processing of interleukin-1 family cytokines: variations on a common theme.
        Immunity. 2015; 42: 991-1004https://doi.org/10.1016/j.immuni.2015.06.003
        • Jasim H
        • Carlsson A
        • Gerdle B
        • Ernberg M
        • Ghafouri B.
        Diurnal variation of inflammatory plasma proteins involved in pain.
        Pain reports. 2019; 4 (e776): e776-https://doi.org/10.1097/PR9.0000000000000776